Contact
Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)
Key regions: United States, China, Germany, Japan, Europe
The Pharmaceuticals market in Paraguay has been experiencing steady growth in recent years.
Customer preferences: Customers in Paraguay have a strong preference for generic drugs due to their lower cost compared to branded drugs. This trend is driven by the high poverty rate in the country, which limits the purchasing power of many Paraguayans. Additionally, the population tends to favor traditional medicine and natural remedies, which has limited the growth of the pharmaceutical market in the country.
Trends in the market: The Paraguayan pharmaceutical market has been growing steadily due to increased access to healthcare services and a growing population. The market is dominated by generic drugs, which account for the majority of sales. However, there has been a recent trend towards the use of more specialized drugs, particularly in the treatment of chronic diseases such as diabetes and hypertension. This trend is expected to continue as the population ages and the burden of chronic disease increases.
Local special circumstances: One of the unique features of the Paraguayan pharmaceutical market is the prevalence of informal drug sales. Many Paraguayans purchase drugs from street vendors or informal markets, which can pose a significant risk to public health. This is due in part to the lack of regulation and oversight in the market, which has allowed unlicensed vendors to operate freely.
Underlying macroeconomic factors: The Paraguayan economy has been growing steadily in recent years, which has contributed to the growth of the pharmaceutical market. However, the country still faces significant challenges, including high levels of poverty and limited access to healthcare services. These factors have limited the growth of the market and will continue to be a challenge for the industry moving forward. Additionally, the lack of regulation and oversight in the market has made it difficult for pharmaceutical companies to operate in the country, which has limited investment and innovation in the industry.
Data coverage:
Data encompasses B2B, B2G, and B2C spend. Figures are based on drug revenues allocated to the country where the money is spent. Monetary values are given at manufacturer price level excluding VAT.Modeling approach / Market size:
Market sizes are determined by a top-down approach, based on a specific rationale for each market. As a basis for evaluating markets, we use financial information of the key players by market. Next, we use relevant key market indicators and data from country-specific associations, such as industry associations. This data helps us estimate the market size for each country individually.Forecasts:
In our forecasts, we apply diverse forecasting techniques. The selection of forecasting techniques is based on the behavior of the particular market. For example, forecasts are based on historical developments, current trends, and key market indicators, using advanced statistical methods. The main driver is healthcare expenditure. Expiring patents and new drugs in the pipeline are also considered.Additional notes:
Data is modeled in US$ using current exchange rates. The market is updated twice per year in case market dynamics change. The impact of the COVID-19 pandemic is considered at a country-specific level. This market comprises prescription drugs and all OTC drugs covered in the Statista OTC Pharmaceuticals market. However, in the OTC Pharmaceuticals market, revenues are based on end-consumer prices.Mon - Fri, 9am - 6pm (EST)
Mon - Fri, 9am - 5pm (SGT)
Mon - Fri, 10:00am - 6:00pm (JST)
Mon - Fri, 9:30am - 5pm (GMT)
Mon - Fri, 9am - 6pm (EST)